ANNUAL FINANCIAL REPORT 2010 2010 - TiGenix

After the Contribution andafter the OfferingAfter the Contribution and after theOffering on fully diluted basis**FCPR Ventech Capital III 6,234,238 6.84% 6,234,238 6.67%LSP III Omni Investment Coöperatief, U.A. 5,334,063 5.85% 5,334,063 5.71%Ysios Biofund I, FCR 5,712,410 6.27% 5,712,410 6.11%Biopartners Capital, S.L. 3,572,928 3.92% 3,572,928 3.82%Novartis Bioventures Ltd. 6,641,886 7.29% 6,641,886 7.11%Roche Finanz AG 6,641,886 7.29% 6,641,886 7.11%CX EBIP Agreement, S.L. 2,286,172 2.51% 2,286,172 2.45%Subtotal 55,846,024 61.29% 55,846,024 59.78%Other Shareholders 35,276,643 38.71% 37,569,135 40.22%TOTAL 91,122,667 100.00% 93,415,159 100.00%Scenario 2: Existing Shareholders exercise no Preferential RightsAfter the Contribution andafter the OfferingAfter the Contribution and after theOffering on fully diluted basis**Shareholder Number of Shares % Number of Shares %ING België NV 4,253,731 4.67% 4,253,731 4.55%Fagus NV 2,105,527 2.31% 2,105,527 2.25%A. van Herk / O.G.B.B.A. van Herk B.V. 1,685,862 1.85% 1,685,862 1.80%Gemma Frisius-Fonds K.U.Leuven NV 1,224,870 1.34% 1,224,870 1.31%Particon B.V. 340,000 0.37% 340,000 0.36%N.V. Industriebank LIOF 340,000 0.37% 340,000 0.36%Limburg Ventures B.V. 200,000 0.22% 200,000 0.21%LRM NV 200,000 0.22% 200,000 0.21%Genetrix Life Sciences A.B. 5,835,379 6.40% 5,835,379 6.25%FCPR Ventech Capital III 5,195,199 5.70% 5,195,199 5.56%LSP III Omni Investment Coöperatief, U.A. 4,445,053 4.88% 4,445,053 4.76%Ysios Biofund I, FCR 4,760,342 5.22% 4,760,342 5.10%Biopartners Capital, S.L. 2,977,440 3.27% 2,977,440 3.19%Novartis Bioventures Ltd. 5,534,905 6.07% 5,534,905 5.92%Roche Finanz AG 5,534,905 6.07% 5,534,905 5.92%CX EBIP Agreement, S.L. 1,905,144 2.09% 1,905,144 2.04%Subtotal 46,538,357 51.07% 46,538,357 49.82%Other Shareholders 44,584,310 48.93% 46,876,802 50.18%TOTAL 91,122,667 100.00% 93,415,159 100.00%Interest of Natural and Legal PersonsThe Joint Global Coordinators and Bookrunners are expected to enter into an Underwriting Agreement with the Issuer under certainconditions (see section 3.8 of the prospectus).Furthermore KBC Securities (and their affiliates) and Kempen (and their affiliates) have provided, and may provide in the future, variousbanking services, commercial services and other services to the Company.19 •